# Investigating GDF11 and MSTN as candidate circulating geronic factors

> **NIH NIH R01** · HARVARD UNIVERSITY · 2020 · $503,172

## Abstract

Project Summary
Studies using heterochronic parabiosis, a surgical intervention that establishes bi-directional cross-circulation
between young and old animals, strongly indicate the existence of blood-borne factors that regulate the
regeneration and homeostasis of skeletal muscle, and other tissues, in an age-dependent manner. Work from
my lab and others implicate the circulating proteins Growth Differentiation Factor 11 (GDF11) and Myostatin
(MSTN) as candidate geronic factors responsible for the transposition of aging phenotypes in muscle in
heterochronically joined mice.
GDF11 and MSTN are closely related ligands of the TGFβ superfamily that share 89% sequence identity in
their receptor-binding domains and exhibit highly overlapping patterns of receptor binding. Yet despite these
similarities, published reports suggest that these two proteins may exert opposing influences on aging muscle.
In particular, we showed that systemic supplementation of GDF11 levels in aged mice (by injection of
recombinant GDF11 protein) can elicit a striking reversal of age-related deficits in muscle repair capacity,
remodel myofiber ultrastructure, and enhance muscle strength and endurance. GDF11 expression also has
been positively correlated with lifespan in studies of multiple species. Conversely, analyses of MSTN-deficient
animals suggest that MSTN acts normally to limit muscle growth and slow regeneration after injury, and that
mild suppression of MSTN in mice may have a positive impact on lifespan. Importantly, these effects of GDF11
and MSTN appear to be both dose- and context-specific, which has raised some confusion and controversy
regarding their respective influences on aging and health span.
In this proposal, we aim to overcome prior experimental challenges to generate a clear molecular genetic
understanding of the respective roles of GDF11 and MSTN in muscle aging, their mechanistic relationship to
one another, and their relevance as therapeutically actionable geronic proteins. Our studies will use highly
specific LC-MS/MS assays and mouse genetic models to track circulating protein levels and manipulate
GDF11 and MSTN expression in young, middle-aged and aged mice, and in the young or aged partners of
heterochronic parabiosis, both in steady state and in response to muscle injury. The importance of this work is
underscored by human studies linking differences in serum levels of GDF11 and MSTN with clinical outcomes
in several aging-related diseases. As such, our proposed work has a high potential impact for the identification
and future development of promising targets to combat age-related muscle dysfunction and is directly
responsive to RFA-AG-17-002: Characterization of Circulating Pro- and Anti-Geronic Proteins and Peptides.

## Key facts

- **NIH application ID:** 9928385
- **Project number:** 5R01AG057428-04
- **Recipient organization:** HARVARD UNIVERSITY
- **Principal Investigator:** AMY JO WAGERS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $503,172
- **Award type:** 5
- **Project period:** 2017-09-15 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9928385

## Citation

> US National Institutes of Health, RePORTER application 9928385, Investigating GDF11 and MSTN as candidate circulating geronic factors (5R01AG057428-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9928385. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*